Commit Biologics, a Danish biotech developing complement-powered immune engagers, said Nov. 17 that it has closed a $60 million (€54 million) seed financing backed by AbbVie Ventures, M Ventures and Ackermans & van Haaren. The money is meant to carry its lead program, COM002, into first human trials.
Existing investors Bioqube Ventures, Korys and Novo Holdings also took part, according to the company's announcement.
What the round does and doesn't add up to
The Nov. 17 announcement described a final close. European Biotechnology reported the same day that it brings accumulated seed financing to $60 million, which means the €54 million should not be stacked on top of earlier seed money. Commit's two previous seed announcements were a €16 million launch round in May 2024 and a €5.5 million extension from Korys in January 2025, together the €21.5 million it had already disclosed.
CEO Thomas L. F. Montgomery Andresen told BioXconomy on Nov. 18 that the round was oversubscribed. Commit disclosed no valuation.
One figure needs care. Ackermans & van Haaren's own release described a conditional commitment of up to €10.5 million, paid in tranches. That is a ceiling, not cash already in Commit's account.
Fierce Biotech has listed Commit in its 2026 fundraising tracker, which covers rounds of $50 million or more.
Where the money is going

COM002 is the first development candidate to emerge from BiCE, Commit's platform for engaging the complement system, a part of the immune system that helps clear threats. The company nominated it on Nov. 12 and, the same day, appointed Dr. Benjamin Ole Wolthers as head of clinical development.
According to the release, COM002 targets a B-cell antigen. Ackermans & van Haaren's release said the drug is intended to deplete B cells and follicular helper T cells. Commit announced on Nov. 11, 2025, that it had shown proof of concept for the platform in non-human primates. That is preclinical evidence, and it says little yet about whether patients will benefit.

